OECI TuBaFrost tumor biobanking

Peter HJ Riegman¹, Antonio Llombart Bosch², and the OECI TuBaFrost Consortium*

¹Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Center Rotterdam, The Netherlands; ²Fundación Instituto Valenciano de Oncologìa, Valencia, Spain

ABSTRACT

OECI TuBaFrost harbors a complete infrastructure for the exchange of frozen tumor samples between European countries. OECI TuBaFrost consists of:

- · A code of conduct on how to exchange human residual samples in Europe
- A central database application accessible over the Internet (www.tubafrost.org)
 where data can be uploaded and searched from samples that can be selected and
 ordered
- Access rules with incentives for collectors
- Standardization needed to enable the analysis of high quality samples derived from different centers
- Virtual Microscopy to support sample selection with difficult pathology

The entire infrastructure was, after completion, which was entirely financed by the European Commission, implemented in the OECI. But so far it has not been used to its capacity. A recent survey held amongst the OECI members shed light on the causes. The main conclusion is that all responders see OECI TuBaFrost as a good platform for exchange of samples, however, the biggest bottleneck found was that potential users are too unfamiliar with the communication between their own biobank tracking system and the TuBaFrost central database application. Therefore, new future plans are drawn. In addition, new infrastructure plans have been developed and the first preparatory steps have been set. For biobanks the BBMRI project has started aiming for Pan-European Biobanking and Biomolecular Resources Research Infrastructure.

*The OECI TuBaFrost Consortium

PHJ Riegman^a, WNM Dinjens^a, MHA Oomen^a, A Spatz^b, C Ratcliffe^c, K Knox^c, R Mager^{c,d}, D Kerr^c, F. Pezzella^d, B van Damme^e, M van de Vijver^f, H van Boven^f, MM Morente^g, S Alonso^g, D Kerjaschki^h, J Pammer^h, JA Lopez-Guerreroⁱ, A Llombart Boschⁱ, A Carboneⁱ, A Gloghini^j, I Teodorovic^k, M Isabelle^k, D Jamine^k, A Passioukov^k, S Lejeune^k, P Therasse^k, EB van Veen^l, KH Lam^a, JW Oosterhuis^a

^aErasmus MC. Rotterdam. The Netherlands; bInstitut Gustave Roussy, Villejuif, France; 'National Translational Cancer Research Network, University of Oxford, Radcliffe Infirmary, Oxford, United Kingdom; dNuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; eUZ-KU-Leuven, Leuven, Belgium: fNetherlands Cancer Institute, Amsterdam, The Netherlands; 9Centro Nacional de Investigaciones Oncologicas, Madrid, Spain; hAllgemeines Krankenhaus, University of Vienna, Austria; ⁱFundacion Instituto Valenciano de Oncologìa, Valencia, Spain; ^jCentro di Riferimento Oncologico, Aviano (PN), Italy; kEORTC Data Center, Brussels, Belgium; Medlaw Consult, Den Haag, The Netherlands.

Key words: disease-oriented biobanking, virtual bio repository, tumor bank, biobank network, cancer research infrastructure.

Correspondence to: Peter HJ Riegman PhD; Head Erasmus MC Tissue Bank; Co-ordinator of the European Human Frozen Tumor Tissue Bank (OECI/TuBa-Frost). Department of Pathology, Josephine Nefkens Institute, Be 235b Erasmus Medical Center, PO box 2040, 3000CA Rotterdam, The Netherlands.

E-mail p.riegman@erasmusmc.nl Web sites http://www.tubafrost.org http://www.eur.nl/fgg/pathol/